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Introduction
Parkinson's disease (PD) is the second most common
neurodegenerative disorder after Alzheimer's disease.
Neurodegenerative disorders are characterized by a
progressive and specific loss of neurons. PD results
from the progressive degeneration of dopamine neu-
rons that innervate the striatum [1]. Alteration of the
postural reflex, bradykinesia, muscle rigidity and rest-
ing tremor are clinical symptoms that characterize this
disease [2]. Furthermore, clinical symptoms appear
after 50-60% of neuronal loss, cell death and degener-
ation in the Substantia nigra (SN) [3]. Since age is a
consistent risk factor, an age-dependent cumulative
insult mechanism may be responsible for the selective
degeneration of nigrostriatal neurons. Moreover, the
increase of free radicals with age is the reason for the
decrease in concentration of the polyunsaturated fatty
acid (PUFA) in the cell membrane. Supplementation
of the diet with these PUFAs may help to delay
changes associated with neurodegenerative diseases
such as PD [4]. 
Docosahexaenoic acid (DHA) is the major PUFA in
the phospholipids fraction of the brain and is required
for normal neuronal function [5]. Maintaining concen-
trations of this PUFA is essential for enhanced cogni-
tive, learning and memory functions. Neurodegenera-
tive disorders such as PD, often exhibit significant
declines in DHA and other PUFAs, which may in part,
contribute to some of the observed declines in brain
functions [6]. Considerable effort has been devoted to
the search for molecules that might exert trophic influ-
ences on midbrain dopamine neurons, and potentially
be of therapeutic value in the treatment of PD. 
Glial cell line-derived neurotrophic factor (GDNF)
was originally identified as a survival factor for mid-
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brain dopaminergic neurons [7]. The members of the
GDNF family is composed of GDNF, neurturin
(NTN), persephin (PSP), and artemin (ART) [7], of
which GDNF and NTN are responsible for the devel-
opment and survival of the enteric neurons, and NTN
for parasympathetic neurons [8]. GDNF promotes
recovery of the injured nigrostriatal dopaminergic sys-
tem and improves motor functions in rodent and non-
human primate models of PD [8]. GDNF and NTN are
very potent trophic factors [9] and they have been
shown to exert neuroprotective effects on lesioned
nigral dopaminergic neurons for PD [8].
The aim of the study in light of this knowledge was
to evaluate the neuroprotective effects of GDNF and
NTN by investigating their immunolocalization after
administration of DHA to a rat model of PD. For this
reason we hypothesized that DHA administered to a rat
model of PD might alter GDNF and NTN expression
in SN. 
Materials and methods
Animals. A total of 24 adult Wistar male rats (380-420 g) were
housed at 22-24°C under controlled conditions with free access to
standard rat chow and water. The experimental protocol was
approved by the animal care and usage comittee of Akdeniz
University and was in accordance with the Declaration of Helsinki
and International Association for the Study of Pain Guidelines.
Experimental protocol. In this study 1-methyl-4-phenyl-1, 2, 3,
6-tetrahydropyridine (MPTP) neurotoxin that induces dopaminer-
gic neurodegeneration was used to create a model of Parkinson's dis-
ease. Significantly, this model closely mimics the clinical symptoms
found in PD that is more closely related to human Parkinsonism.
The rats were randomly divided into 4 groups as follows: 
(1) Control, (2) DHA-treated (DHA), (3) MPTP-induced (MPTP),
(4) MPTP induced+DHA treated (MPTP+DHA). DHA (D2534,
Sigma-Aldrich, St. Louis, MO, USA) was dissolved in corn oil at
a concentration of 0.046 M and was given to the treatment groups
for 30 days (36 mg/kg/day) by gavage [10]. In order to eliminate
the effects of daily gavage and vehicle; other groups received a
similar volume of corn oil alone. Three weeks after gavage proce-
dure, MPTP and MPTP+DHA animals were anesthetized with 400
mg/kg chloral hydrate (K91627425, Merck KGaA, Darmstadt,
Germany) intraperitoneally. MPTP (M-0896, Sigma-Aldrich, St.
Louis, Mo,USA ) (100 g/1 l saline) was infused bilaterally into the
medial forebrain bundle using a Hamilton microsyringe at a rate of
0.33 l/min [11], according to the following coordinates adapted
from the Pellegrino's atlas [12]: anteroposterior (AP)  2.2 mm from
the bregma, mediolateral (ML) ±1.5 mm from midline and
dorsoventral (DV)  8.0 mm from the skull. After surgery, animals
were allowed to recover from anesthesia in a temperature con-
trolled chamber and then placed in individual cages. The observers
were blind to the type and source of rat/tissue examined.
Tests of motor activity. Seven days after the creation of the exper-
imental PD model, motor activity of the rats was investigated using
the "vertical pole" and "vertical wire" tests. The results of these test
confirmed that the created model of PD was reliable.
For the vertical pole test, the animal was placed face up on a
cloth-tape-covered pole (3.0 cm diameter, 150 cm length), which
was held in a horizontal position, then the pole was gradually lift-
ed to a vertical position and the time a rat stayed on the pole was
recorded for a maximum of 120 s. In this test, the animal with
deficits in motor coordination and balance will fall off the pole
[13].
We also analyzed the rat catalepsy state on vertical wire netting
(size 56.5 × 23.5 cm; mesh 1 × 1 cm; wire diameter 2 mm). The
rats were placed with all paws on the wire net and the time taken
for at least one paw to be actively displaced from the bar (descent
latency) was determined [14].
Tissue collection. At the end of the treatment period and physio-
logical tests, rats were anesthetized with a combination of keta-
mine (80 mg/kg, i.p.) and xylazine (15 mg/kg, i.p.), perfused tran-
scardially with heparinized saline and brains were removed imme-
diately. The samples were fixed immediately in formalin at room
temperature for 8 h. dehydrated in ascending ethanol series, and
embedded in paraffin for immunohistochemical analysis. 5-μm
thick sections were collected onto poly-l-lysine-coated slides
(Sigma-Aldrich, St. Louis, MO, USA).
Immunohistochemistry. We used tyrosine hydroxylase (TH)
immunoreactivity to mark dopaminergic neurons in SN of PD
model. For GDNF, NTN and TH immunohistochemistry, paraffin
sections were deparaffinized, rehydrated and blocked for endoge-
nous peroxidase activity with methanol containing 3% H2O2 for
15 min and for nonspecific binding with universal blocking reagent
(BioGenex, San Ramon, CA, USA) for 10 min at room tempera-
ture [15]. Anti-rabbit GDNF (sc #9010), anti-goat NTN (sc #8173)
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted in dilu-
tion buffer (1/250) or mouse anti-TH (Calbiochem, CA, USA
#657010) (1/100) were applied for 1h at room temperature in a
humidified chamber. For negative controls the primary antibodies
were replaced by appropriate isotype antibodies at the same con-
centration. After several washing steps in PBS, sections were incu-
bated with biotinylated goat anti-rabbit IgG or biotinylated horse
anti-goat IgG secondary antibody (1/400 dilution Vector Lab.
Burlingame, CA, USA) for 30 min followed by LSAB strepta-
vidin-peroxidase complex (Dako, Carpinteria, CA, USA) incuba-
tion for 30 min and were rinsed with PBS. Antibody-antigen com-
plexes were visualized by incubation with diaminobenzidine
(DAB) chromogen (BioGenex). Sections were counterstained with
Mayer's hematoxylin (Dako), dehydrated, mounted and examined
by a Zeiss-Axioplan (Oberkochen, Germany) microscope.
Evaluation of tyrosine hydroxylase (TH)-positive neurons. To
assay changes in the number of dopaminergic neurons in the SN,
the total numbers of TH-stained neurons were counted independ-
ently by two observers blinded to the type and source of the tissues
under a light microscope (40X magnification) in six slides from
each of the groups. The intra-individual and inter-individual coef-
ficients of variation were 7 and 10%, respectively, for the evalua-
tion. The average of counts was presented. 
Semi-quantitative analysis of staining intensities. The intensity for
TH, GDNF and NTN immunoreactivity was semi-quantitatively
evaluated using the following intensity categories: no staining (-),
weak but detectable staining (+), moderate or distinct staining (++),
strong or intense staining (+++). The data are presented in Table 1.
Statistical analysis. Differences in motor behavior among groups
were compared by non-parametric Kruskal-Wallis test, followed
by post hoc Mann-Whitney U test. The data from TH-positive neu-
ron counts were normally distributed as tested by Kolmogorov-
Smirnoff test and therefore, were analyzed with Student's t-test or
one-way ANOVA, followed by post hoc Holm-Sidak test when
appropriate. All statistical analyses were performed using Sigmas-
tat for Windows, version 3.0 (Jandel Scientific Corporation, San
Rafael, CA). Data are presented as the mean ± SEM. Differences
were considered to be significant at p<0.05. 
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A significant (p<0.05) decrease in motor activity was
found in the groups with experimental Parkinsonism
when compared to the control (Fig. 1A, B). In the ver-
tical pole test, control (120 sec) and DHA (107.6±6.8
sec) rats held the pole firmly while the pole reached a
90° angle. MPTP (41.67±9.81 sec) animals tended to
fall off in less than 40s. Nevertheless, the pole test
latency was significantly increased in the
MPTP+DHA (101.33±11.07 sec) group as compared
to MPTP group. As presented in Fig. 1B, descent laten-
cy in the catalepsy test was significantly greater in
MPTP (23.83±6.68 sec) rats than in control (1.33±0.33
sec) and DHA (1.83±0.31 sec) rats. Moreover, the
cataleptic state was significantly decreased in
MPTP+DHA (9.17±1.68 sec) group when compared to
MPTP group.
Tyrosine hydroxylase immunohistochemistry
MPTP caused an obvious reduction in TH positive
dopaminergic neuron viability as determined at day 7.
The neuron numbers of the control group (Fig. 2A, E)
were almost equivalent to the DHA group (Fig. 2D, H).
Dopaminergic neuron numbers were clearly decreased
in the MPTP group (Fig. 2B, F). DHA supplementation
was effectively decreasing the dopaminergic neuron
death in the MPTP+DHA group (Fig. 2C, G). 
The compact, reticular and lateral parts of rat SN
were easily distinguished by TH immunostaining. The
immunoreactivity for TH was observed in neuron bod-
ies and processes. No immunoreactivity was observed
in glial cells and the endothelium. No differences in
TH staining intensities were observed among groups.
The staining intensities for TH immunoreactivity are
presented in Table 1.
The immunostaining was quantitatively evaluated
with the positive dopaminergic neuron staining with
TH counted according to the experimental groups. The
immunolabelling was significantly decreased in the
MPTP group (152±2) that were found to be sparse and
disorganized when compared to the control and DHA
groups (p<0.05). In the MPTP+DHA group (309±2.4),
the neuron processes were more organized and neuron
number was significantly higher when compared to the
MPTP group (p<0.05). In addition, TH immunoposi-
tive neuron number was higher in DHA groups
(442±1.5) than the control groups (399±3). No staining
was observed in the negative sections. Since the data
from the TH positive cell counts were normally dis-
tributed, therefore one way ANOVA was used. Statis-
tical calculations were performed using SigmaStat for
Windows, version 3.0 (Jandel Scientific Corp. San
Rafael, CA). Statistical significance was defined as
p<0.05. The results are presented in Table 2.
Immunostaining of GDNF and NTN in SN
Immunohistochemical localizations of GDNF and
NTN were prominent in the cytoplasm of dopaminer-
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Table 1. Semi-quantitative evaluation of immunostaining intensi-
ties. Staining intensity categories: (-)no staining, (+)weak but
detectable staining, (++) moderate or distinct staining, (+++)
strong or intense staining.
Table 2. Representative table presents tyrosine hydroxylase
immunopositive dopaminergic neuron numbers
The data are presented as Mean±SEM. a MPTP group was significantly
lower than that of control and DHA groups (p<0.05). b MPTP+DHA group
was significantly higher than that of MPTP group (p<0.05). 
Fig. 1. The comparison of motor activities using vertical pole test
(A); vertical wire test (B). C; Control, D; DHA group, MPTP,
MPTP+DHA group. Data are expressed as means ± S.E. A. P<0,05
vs control group, B. P<0.05 vs MPTP group.
gic neurons with an increased expression in
MPTP+DHA when compared to the MPTP groups. 
Although, the dopaminergic neuron staining inten-
sities were decreased in the MPTP group compared to
the control (Fig. 3A vs 3B, Table 1), GDNF protein
immunoreactivity was still present in MPTP treated
neurons. Moreover, strong immunostaining for GDNF
was observed in both the MPTP+DHA and DHA
groups when compared to the MPTP group (Fig. 3C,
D, 4C,D) NTN staining intensity was also decreased in
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Fig. 2. Localization of tyrosine hydroxylase protein in dopaminergic neurons was presented. A,E,K. Control, B,F,L. MPTP, 
C,G,M. MPTP+DHA, D,H,N. DHA group. Magnification: A,B,C,D: ×2.5; E,F,G,H: ×40; K,L,M,N: ×20. Tyrosine hydroxylase
immunoreactivity in the control group was almost the same as in MPTP+DHA group, which both were higher than that of the MPTP
group. Scale bar represents 100 μm.
MPTP group compared to the MPTP+DHA, DHA and
control groups (Fig. 5A-H and Table 1). 
Discussion
The etiology of PD is probably a combination of envi-
ronmental and genetic factors. MPTP represents the
most important and most frequently used Parkinsonian
toxin applied in animal models. The MPTP treatment
affects mitochondria, either by inhibiting mitochondr-
ial complex I or complex III [16] which leads to a sig-
nificant reduction in the number of neurons in the Sub-
stantia nigra pars compacta (SNpc) [17]. In this study,
we have also emphasized the reduction in TH-positive
neuron numbers in the experimental PD model created
by the toxic effects of MPTP in SN. TH is the rate-lim-
iting enzyme in catecholamine synthesis. The most
densely packed TH-positive cell area in the brain is the
SNpc, which projects fibers to the striatum [18]. Since
it has been shown that the cell-body rich SNpc prima-
rily contains the soluble form of the TH enzyme, it is
often used as the phenotypic marker for dopaminergic
neuron numbers and can be measured both by bio-
chemical and immunohistochemical methods to deter-
mine neuron loss [19].
Studies in animals clearly show that oral intake of
DHA can alter brain DHA concentrations and thereby
modify brain functions that is associated with memory
loss and diminished cognitive function [20]. This pro-
vides us with an opportunity to use DHA as a nutraceu-
tical or pharmaceutical tool in brain disorders such as
PD [21]. Based on this hypothesis, we aimed to investi-
gate the presence of DHA effects on dopaminergic neu-
rons in SN after induced experimental Parkinson model,
by using TH immunohistochemistry. Our TH immuno-
histochemistry results clearly indicated that chronic pre
administration of DHA may partially restore dopamin-
ergic neuron numbers in this experimental model of PD. 
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Fig. 3. Immunolocalization of GDNF in substantia nigra. A. Control, B. MPTP, C. MPTP+DHA, D. DHA group. Magnification: 20x. The
immunoreactivity of GDNF was found to be higher in MPTP+DHA groups when compared to MPTP groups. In DHA group (D), the
GDNF reactivity was higher than control group.
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Fig. 4. Representative pictures were presented in a higher magnification (×40). A-D. GDNF immunolabelling in 4 groups. A, E. Control
group. B, F. MPTP group. C,G. MPTP+DHA group. D, H. DHA group. Scale bar represents 100 μm.
Fig. 5. Immunolocalization of NTN in substantia nigra. A. Control, B. MPTP, C. MPTP+DHA, D. DHA group. Magnification: ×20. NTN
expression was cyctoplasmic and the expression was decreased in MPTP group compared to the MPTP+DHA group. Control and DHA groups
had intense reactivity (A, D). E-H) A higher magnification of NTN immunolocalization was presented (×40). Scale bar represents 100 μm.
We have also evaluated the motor activity in the
experimental Parkinsonism model. Measurement of
motor activity in experimental Parkinsonism models
depends on the performance of animals in well defined
tasks. The results of these test confirmed that the cre-
ated model of PD was reliable. In our current study,
MPTP-treated rats displayed typical behavioral char-
acteristics of PD in the vertical pole and catalepsy test.
The present findings are in agreement with results
from previous studies which demostrated the impair-
ment of motor activity in MPTP induced Parkinsonism
model [22]. On the other hand DHA pre-administra-
tion reduced these symptoms in the MPTP group. This
indicates a relationship between maintenance of TH
positive cells and diminished Parkinsonism symptoms
that were detected in the MPTP+DHA group. This
DHA dose was selected from a previous study
designed to represent human administration of high
levels of DHA.
Neurotrophic factors regulate many critical aspects
of the ontogeny of neurons, such as promoting sur-
vival, neurite branching and synaptogenesis [23]. One
of those neurotrophic factors is GDNF which pro-
motes the survival of the embryonic dopaminergic
neurons of the midbrain during PD [24]. Therefore this
trophic factor raised great expectations as a potential
therapeutic agent for the treatment of neurodegenera-
tive diseases [25]. In this study we have localized
GDNF protein in the cytoplasm of dopaminergic neu-
rons in SN. It is possible that the strong expression of
GDNF in dopaminergic neurons might be related to its
therapeutic effects in PD and might indicate that
GDNF can successfully block the already initiated
degenerative process in the SN. Our results showing
the immunostaining of GDNF are consistent with the
previous report by Zigmond et al. where they have
shown the expression of GDNF in dopaminergic neu-
rons suggesting a possible therapeutic effect. Further-
more, our results support Grondin and Gash (1998)
who reported that GDNF rescues the dopaminergic
neurons from the neurotoxin-induced death and stimu-
lates functional recovery in an animal model of PD. 
GDNF and the related factor NTN support several
neuronal populations in the central nervous system,
including midbrain dopamine neurons and motor neu-
rons. In addition, these promote survival and regulate
differentiation of many peripheral neurons [26].
GDNF and NTN can act as target derived trophic fac-
tors for dopaminergic neurons. These two factors show
different and overlapping effects, because GDNF is a
potent survival, neuritogenic and hypertrophic factor,
while NTN only induces survival-promoting effect on
nigral neurons [23]. Supporting these previous studies,
we have observed that DHA treatment was effective in
preventing the death of nigral dopaminergic neurons,
likely to be shown with GDNF and NTN immunos-
taining intensities. Unfortunately, the exact mecha-
nism of how DHA affects GDNF and NTN up-regula-
tion is still unknown. Therefore, further functional
studies are needed to clarify this issue. 
In conclusion, DHA supplementation in MPTP-
induced experimental Parkinsonism model significant-
ly protects dopaminergic neurons against cell death by
increasing the expressions of GDNF and NTN. Our
data show that oral administration of DHA can prevent
the loss in dopaminergic neurons. Moreover, the neu-
roprotective effects of GDNF and NTN combined with
DHA will lead to better strategies for the treatment of
neurodegenerative diseases. The present result is in
agreement with results from previous studies which
demonstrated a DHA enriched diet increased levels of
brain derived neurotrophic factor (BDNF) [27]. The
powerful neuroprotective and neurorestorative proper-
ties of GDNF and NTN suggest that tropic factors may
play an important role in treating PD. We speculate
that DHA administration prevents GDNF and NTN
labelled dopaminergic neuron loss in an animal PD
model.
Whereas the knowledge on the therapeutic poten-
tial of neurotrophic factors such as GDNF and NTN is
still contradictory, it should be known that we are only
at the beginning of the story. 
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